UNSPSC 51351606: Dienogest

This classification denotes a therapeutic progestin with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46M3EV8HHE, chemically known as 19-norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17-alpha)- but generally known as dienogest, which bears US NIH Compound Identifier 68861. European Medicines Agency schedules Dienogest in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07108MIG.

UNSPSC 51351606 Dienogest is a Commodity code that captures state and local procurement of specific pharmaceutical products, including hormone-based medications and their generic equivalents, distributed through cooperative purchasing frameworks to government health and human services facilities. The recent solicitation activity shows that state and local buyers under this code are purchasing generic multi-source pharmaceuticals and over-the-counter products through established wholesaler networks, with vendors supplying products identified by National Drug Code (NDC), requiring cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and contractual relationships with authorized distributors. The issuing bodies are primarily state-level cooperative purchasing alliances administering contracts on behalf of multiple participating jurisdictions, including state agencies, local government facilities, and health systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the most recent representative opportunity — a Request for Proposal (RFP) posted January 20, 2026, due March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products with distribution across participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and submit pricing in flat-price, net-price, or WAC-minus formats through the ePro procurement system by March 26, 2026. The contract term is two years with optional extensions, effective July 1, 2026, with pricing weighted at 75 percent of evaluation criteria, and awarded vendors subject to a 3 percent administrative fee on all purchases and performance penalties ranging from $200 to $1,500 per violation.